Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | RBP4 | P02753 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6442530 | 0.84 | L3MBTL1 (0.43) | L3MBTL1CYP2C9CYP3A4DPP4DPP9 | |
| SCHEMBL6443103 | 0.84 | L3MBTL1 (0.42) | L3MBTL1CYP2C9CYP3A4DPP4DPP9 | |
| SCHEMBL6441836 | 0.81 | L3MBTL1 (0.41) | L3MBTL1CYP2C9CYP3A4DPP4DPP9 | |
| SCHEMBL6441424 | 0.79 | L3MBTL1 (0.49) | L3MBTL1CYP2C9CYP3A4DPP4DPP9 | |
| SCHEMBL6441395 | 0.79 | L3MBTL1 (0.39) | L3MBTL1CYP2C9CYP3A4DPP4DPP9 | |
| SCHEMBL6443074 | 0.78 | CYP2C9 (0.55) | CYP2C9CYP3A4CYP2C19CYP1A2CYP2C8 | |
| SCHEMBL6441276 | 0.77 | CYP2C9 (0.51) | CYP2C9CYP3A4CYP2C19CYP1A2CYP2C8 | |
| SCHEMBL6442558 | 0.77 | CYP2C9 (0.49) | L3MBTL1CYP2C9CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL6473347 | 0.76 | CYP2C9 (0.47) | L3MBTL1CYP2C9CYP3A4DPP4DPP9 | |
| SCHEMBL6443079 | 0.76 | L3MBTL1 (0.46) | L3MBTL1CYP2C9CYP3A4DPP4DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002004440-A9 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2005-11-03 | — | — | WO | claimed |
| EP-1299382-B1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2005-09-21 | — | — | EP | claimed |
| US-6573262-B2 | Compounds for treating mammals infected with HIV virus | BRISTOL-MYERS SQIBB COMPANY | 2003-06-03 | — | — | US | claimed |
| US-20030069245-A1 | Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2003-04-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069245-A1 | Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives | IDO1, IDO2, ITPA | L3MBTL1 4725/4885CYP2C9 2370/4885CYP3A4 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.